Effect of respiratory virus infections including rhinovirus on clinical status in cystic fibrosis.

Smyth, Alan; Smyth, Rosalind L; Tong, C. Y. William; Hart, C. A.; Heaf, D P

doi:10.1136/adc.73.2.117

Cited by 160 publications

(148 citation statements)

References 12 publications

Supporting

Mentioning

140

Contrasting

Unclassified

Order By: Relevance

Section: Iiib3 Respiratory Virusesmentioning

confidence: 99%

“…In adults and children with CF, viral infections can trigger pulmonary exacerbations, [269][270][271][272] particularly influenza virus 271,273 and rhinovirus. 269,270 Exacerbations in which a virus is identified are associated with worse clinical severity compared with viral exacerbations. 274 As sensitive viral detection methods like real-time PCR become increasingly available and identify a broader range of viruses, 275 the role played by other viral pathogens (eg, coronavirus and human metapneumovirus) in CF exacerbations will be further elucidated.…”

Section: Iiib3 Respiratory Virusesmentioning

confidence: 99%

See 1 more Smart Citation

Infection Prevention and Control Guideline for Cystic Fibrosis: 2013 Update

Saiman

Siegel

LiPuma

et al. 2014

Infect. Control Hosp. Epidemiol.

345

382

View full text Add to dashboard Cite

The 2013 Infection Prevention and Control (IP&C) Guideline for Cystic Fibrosis (CF) was commissioned by the CF Foundation as an update of the 2003 Infection Control Guideline for CF. During the past decade, new knowledge and new challenges provided the following rationale to develop updated IP&C strategies for this unique population:1. The need to integrate relevant recommendations from evidence-based guidelines published since 2003 into IP&C practices for CF. These included guidelines from the Centers for Disease Control and Prevention (CDC)/Healthcare Infection Control Practices Advisory Committee (HICPAC), the World Health Organization (WHO), and key professional societies, including the Infectious Diseases Society of America (IDSA) and the Society for Healthcare Epidemiology of America (SHEA). During the past decade, new evidence has led to a renewed emphasis on source containment of potential pathogens and the role played by the contaminated healthcare environment in the transmission of infectious agents. Furthermore, an increased understanding of the importance of the application of implementation science, monitoring adherence, and feedback principles has been shown to increase the effectiveness of IP&C guideline recommendations.2. Experience with emerging pathogens in the non-CF population has expanded our understanding of droplet transmission of respiratory pathogens and can inform IP&C strategies for CF. These pathogens include severe acute respiratory syndrome coronavirus and the 2009 influenza A H1N1. Lessons learned about preventing transmission of methicillin-resistant Staphylococcus aureus (MRSA) and multidrug-resistant gram-negative pathogens in non-CF patient populations also can inform IP&C strategies for CF.

show abstract

Section: Iiib3 Respiratory Virusesmentioning

confidence: 99%

Section: Iiib3 Respiratory Virusesmentioning

confidence: 99%

Infection Prevention and Control Guideline for Cystic Fibrosis: 2013 Update

Saiman

Siegel

LiPuma

et al. 2014

Infect. Control Hosp. Epidemiol.

345

382

View full text Add to dashboard Cite

show abstract

“…Infections with respiratory viruses (eg, influenza and rhinoviruses) are associated with exacerbation of pulmonary problems, disease progression, and increase in bacterial adherence in CF airways, which predisposes to secondary bacterial infection. [7][8][9][10] Once infected with respiratory viruses, children with CF are affected for longer periods and more severely than healthy children. 11 During the influenza pandemic, patients with CF had an increased morbidity and a higher case fatality compared with patients with other chronic respiratory diseases or to healthy control subjects.…”

mentioning

confidence: 99%

Safety of Live-Attenuated Influenza Vaccination in Cystic Fibrosis

et al. 2014

View full text Add to dashboard Cite

OBJECTIVES: Given the improved efficacy of the nasal live-attenuated influenza virus vaccine (LAIV) compared with the injectable vaccine in children, we aimed to determine its safety in individuals with cystic fibrosis (CF). METHODS: A cohort of 168 study participants, aged 2 to 18 years with CF, vaccinated with LAIV between October 1, 2012, and January 30, 2013, was followed prospectively for 56 days after initial vaccination in 3 pediatric CF clinics across the province of Quebec. Days 0 to 28 post-LAIV were considered the at-risk period for all outcomes of interest, and days 29 to 56 post-LAIV were considered the non–at-risk period. Incident respiratory deteriorations were defined as an unscheduled medical visit, hospitalization, or a new course of oral antibiotics for respiratory complaints. Using a self-controlled design, incidence rate ratios (IRR) were used to compare at-risk and non–at-risk periods. RESULTS: Comparing at-risk to non–at-risk periods, there was no significant increase in the rate of incident respiratory deteriorations (IRR, 0.72; 95% confidence interval, 0.11–4.27) or all-cause hospitalizations (IRR, 1.16; 95% confidence interval, 0.30–4.81). A greater proportion of participants reported experiencing at least 1 minor respiratory and/or systemic adverse event after immunization during the at-risk period compared with the non–at-risk period (77% vs 54%, respectively). During the first week after LAIV, 13 of 168 (8%) children reported some wheezing, with the vast majority, 9 of 13 (69%), on the day of vaccination. CONCLUSIONS: There was no increased risk of respiratory deterioration or all-cause hospitalization associated with LAIV in our study population. LAIV seems well tolerated in children and adolescents with CF.

show abstract

“…These methods are relatively insensitive and more recent studies have utilised PCR based methodologies (Smyth, Smyth et al 1995;Collinson, Nicholson et al 1996;Punch, Syrmis et al 2004;Olesen, Nielsen et al 2006;). All these studies produced different results in terms of prevalence of respiratory viruses in CF.…”

Section: Viral Respiratory Infections In Cfmentioning

confidence: 99%

“…The viruses implicated in causing respiratory symptoms in CF include RSV, adenovirus, PIV (Types 1 to 4) , influenza A&B, rhinovirus (Ramsey, Gore et al 1989;Smyth, Smyth et al 1995;Collinson, Nicholson et al 1996;) and more recently metapneumovirus (Garcia, Hiatt et al 2007). RSV represents 9-58% of all reported viral infection in CF, with the highest incidence in young children (Armstrong, Grimwood et al 1998).…”

Section: Viral Respiratory Infections In Cfmentioning

confidence: 99%